Literature DB >> 25678021

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Jean-Claude Trinchet1, Valérie Bourcier1, Cendrine Chaffaut2, Mohand Ait Ahmed1, Setty Allam3, Patrick Marcellin4, Dominique Guyader5, Stanislas Pol6, Dominique Larrey7, Victor De Lédinghen8, Denis Ouzan9, Fabien Zoulim10, Dominique Roulot11, Albert Tran12, Jean-Pierre Bronowicki13, Jean-Pierre Zarski14, Odile Goria15, Paul Calès16, Jean-Marie Péron17, Laurent Alric18, Marc Bourlière19, Philippe Mathurin20, Jean-Frédéric Blanc21, Armand Abergel22, Lawrence Serfaty23, Ariane Mallat24, Jean-Didier Grangé25, Catherine Buffet26, Yannick Bacq27, Claire Wartelle28, Thông Dao29, Yves Benhamou30, Christophe Pilette31, Christine Silvain32, Christos Christidis33, Dominique Capron34, Gérard Thiefin35, Sophie Hillaire36, Vincent Di Martino37, Pierre Nahon1, Sylvie Chevret2.   

Abstract

UNLABELLED: Various critical events, liver related or not, occur in patients with compensated cirrhosis, but their respective burden remains to be prospectively assessed. The aim of this prospective cohort study involving 35 French centers was to capture the whole spectrum of complications occurring in compensated viral cirrhosis (VC) using competing risks analyses. Inclusion criteria were: histologically proven cirrhosis resulting from hepatitis C virus (HCV) or hepatitis B virus (HBV); Child-Pugh A; and no previous hepatic complications. The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events were estimated in a competing risks framework. A total of 1,654 patients were enrolled from 2006 to 2012 (HCV, 1,308; HBV, 315; HCV-HBV, 31). During a median follow-up of 34 months, at least one liver nodule was detected in 271 patients, confirmed as hepatocellular carcinoma (HCC) in 128 (4-year cumI: 10.5%) and cholangiocarcinoma in 3. HCC incidence was higher in HCV (4-year cumI: 11.4% vs. 7.4%; P = 0.05). HCC fulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%. Liver decompensation occurred more frequently in HCV patients (4-year cumI: 10.8% vs. 3.6%; P = 0.0004). Virological eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients and was associated with a marked decrease in HCC, decompensation, and bacterial infection incidences. Survival was shorter in HCV patients (4-year cumI: 91.6% vs. 97.2%; P = 0.0002). Death (n = 102; missing data: 6) was attributed to liver disease in 48 (47%; liver cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48 (47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events: n = 5; miscellaneous, n = 20).
CONCLUSION: After 3 years of follow-up, extrahepatic events still explained half of deaths in patients with compensated VC. A strong decrease in complications was linked to virological eradication/control.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25678021     DOI: 10.1002/hep.27743

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

Review 1.  Surveillance for hepatocellular cancer.

Authors:  Anna Roskilly; Ian A Rowe
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

Review 2.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

3.  Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus.

Authors:  M-L Plissonnier; T Lahlali; M Raab; M Michelet; C Romero-López; M Rivoire; K Strebhardt; D Durantel; M Levrero; P Mehlen; F Zoulim; R Parent
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

Review 4.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

5.  First identification of bovine hepacivirus in wild boars.

Authors:  Claudio de Martinis; Lorena Cardillo; Claudia Esposito; Maurizio Viscardi; Lorella Barca; Stefania Cavallo; Nicola D'Alessio; Vito Martella; Giovanna Fusco
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 6.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

7.  Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.

Authors:  Sun Hong Yoo; Jeong Won Jang; Jung Hyun Kwon; Seung Min Jung; Bohyun Jang; Jong Young Choi
Journal:  Clin Mol Hepatol       Date:  2016-12-25

8.  Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.

Authors:  Feng Su; Noel S Weiss; Lauren A Beste; Andrew M Moon; Ga-Young Jin; Pamela Green; Kristin Berry; George N Ioannou
Journal:  J Hepatol       Date:  2020-11-24       Impact factor: 25.083

9.  Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.

Authors:  Neehar D Parikh; Amit G Singal; David W Hutton; Elliot B Tapper
Journal:  Am J Gastroenterol       Date:  2020-10       Impact factor: 12.045

Review 10.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.